GlassScriptPhysician profile
Sanija Bajramovic
NPI 1851341705
$1,748.32
in general payments reported to CMS, 2019-2025
16 companies · $78.80 in 2025
The $78.80 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $235 · 2021: $97.26 · 2022: $133 · 2023: $507 · 2024: $392 · 2025: $78.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.17 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $502.20 | 2019-2023 | Ozempic |
| Amneal Pharmaceuticals LLC | $260.86 | 2024-2025 | Unithroid |
| Ibsa Pharma INC. | $247.71 | 2023-2024 | Tirosint, Tirosint, Licart |
| Abbott Laboratories | $237.96 | 2021-2023 | Freestyle Libre 3 |
| Radius Health, INC. | $121.34 | 2019 | |
| Abbvie INC. | $84.77 | 2023-2024 | Synthroid |
| Mannkind Corporation | $59.40 | 2019 | |
| Lilly USA, LLC | $47.33 | 2023-2024 | Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.07 | 2023-2025 | Jardiance |
| Corcept Therapeutics | $30.04 | 2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $27.93 | 2022-2023 | Recorlev |
| Beta Bionics, INC. | $24.26 | 2024 | Ilet Bionic Pancreas |
| Horizon Therapeutics Plc | $18.93 | 2023 | Tepezza |
| Amgen INC. | $16.99 | 2025 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $13.78 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $13.75 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanija Bajramovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.